Global Acquired Immunodeficiency Syndrome AIDS Share 2025, Forecast To 2034
26 Mar, 2025
How Has the Acquired Immunodeficiency Syndrome AIDS Market Evolved Historically and What is its Current Size?
The acquired immunodeficiency syndrome aids market has seen considerable growth due to a variety of factors.
• The market for acquired immunodeficiency syndrome (AIDS) has seen significant growth in recent years. The market value is projected to increase from $32.09 billion in 2024 to $33.85 billion in 2025, with a compound annual growth rate (CAGR) of 5.5%.
Factors leading to this growth during the historic period include an uptick in HIV infection rates, amplified government financing for HIV therapy, broadening global consciousness efforts, enhanced diagnostic proficiency, and increased backing from non-governmental organizations.
What is the Forecasted Market Size and CAGR for the Acquired Immunodeficiency Syndrome AIDS Market?
The acquired immunodeficiency syndrome aids market is expected to maintain its strong growth trajectory in upcoming years.
• The market for Acquired Immunodeficiency Syndrome (AIDS) is projected to witness robust growth in the upcoming years, rising to $41.57 billion by 2029 at a Compound Annual Growth Rate (CAGR) of 5.3%.
This expected growth during the forecast period is due to a surge in demand for long-lasting injectable treatments, wider acceptance of pre-exposure prophylaxis (PrEP), increased funding towards HIV cure research, wider availability of telemedicine services for HIV patient care, and a greater emphasis on personalized medicine. Additionally, heightened awareness about early HIV diagnosis is also contributing to this growth. The forecast period is set to see trends including a push towards single-tablet regimens, a growing preference for injectable and implantable HIV therapies, increased demand for digital health services in managing HIV, a rising interest in functional HIV cure strategies, and the further integration of artificial intelligence into the process of drug discovery.
What Key Factors and Trends Are Driving The Growth Acquired Immunodeficiency Syndrome AIDS Market?
The escalating instances of HIV infections are anticipated to boost the expansion of the acquired immunodeficiency syndrome (AIDS) market. The term HIV infections denote the situation brought about by the human immunodeficiency virus (HIV), that assaults the immune mechanism, undermining the human body's power to thwart infections and maladies. HIV infections are on the rise due to unprotected sexual encounters with a diseased individual, shared usage of needles or syringes, transfusion of contaminated blood products, engaging in sexual activities with multiple partners, and a deteriorating immune system or already existing sexually transmitted infections. The management of acquired immunodeficiency syndrome (AIDS) assists individuals with HIV infections by endorsing early detection, widening the utilization of effective antiretroviral therapies, augmenting preventive approaches, reinforcing healthcare systems thereby helping to manage the virus spread better. For instance, per the information released by the European Centre for Disease Prevention and Control (ECDC), a Sweden-based agency under the European Union, there were a total of 112,883 HIV diagnoses made in 2023 across 47 out of 53 countries in the region, with 24,731 cases marked in the European Union/European Economic Area (EU/EEA). The crude rate of HIV diagnoses overall touched 12.7 per 100,000 people, showing a 2.4% surge compared to the 12.4 per 100,000 rates seen in 2022. Thus, the rising occurrences of HIV infections are fueling the growth of the acquired immunodeficiency syndrome (AIDS) market.
What Are The Market Segments In The Acquired Immunodeficiency Syndrome AIDS Market?
The acquired immunodeficiency syndrome (AIDS) market covered in this report is segmented –
1) By Type: Human Immunodeficiency Virus 1, Human Immunodeficiency Virus 2
2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion Inhibitors, CCR5 Anatagonists And Post-Attachment Inhibitors, Protease Inhibitors, Integrase Inhibitors, Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis
3) By Route Of Administration: Oral, Parenteral
4) By Application: Hospital Pharmacy, Retail Pharmacy, Other Applications
5) By Distribution Channel: Offline, Online
Subsegments:
1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), HIV-1 Diagnostic Tests, HIV-1 Vaccine Development, HIV-1 Opportunistic Infection Management
2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2, HIV-2 Diagnostic Tests, HIV-2 Surveillance And Epidemiology, HIV-2 Vaccine Research, Management Of HIV-2 Co-Infections
What Trends Are Shaping The Acquired Immunodeficiency Syndrome AIDS Market?
Firms that dominate the acquired immunodeficiency syndrome (AIDS) industry are keen on creating novel therapies like long-acting injectables. Such innovations improve patient adherence, minimize dosing frequency, and offer a more convenient option compared to daily oral antiretroviral therapies. To explain, long-acting injectables are drugs given through injection, formulated to gradually release their potent ingredients over a prolonged duration, permitting less regular dosing than usual oral medicines. For example, GSK plc., a UK-based pharmaceutical giant, in January 2025 received European Commission's approval for a long-lasting injectable treatment named Vocabria (cabotegravir) and Rekambys (rilpivirine). This treatment is sanctioned for adolescents aged 12 years and above living with HIV and is usually delivered through intramuscular injection every one to two months based on the specific treatment program. The extended period nature of these injectables might enhance adherence rates among teenagers finding it hard to follow daily pill routines.
Who Are the Key Players In The Acquired Immunodeficiency Syndrome AIDS Market?
Major companies operating in the acquired immunodeficiency syndrome (AIDS) market are:
• Pfizer Inc.
• Johnson and Johnson
• F. Hoffmann-La Roche Ltd
• Merck & Co. Inc.
• Sanofi SA
• Bristol-Myers Squibb Company
• Abbott
• GSK plc
• Takeda Pharmaceuticals
• Gilead Sciences
• Viatris Inc.
• Teva Pharmaceuticals
• Aurobindo Pharma
• Cipla Ltd
• Shionogi and Co.
• Dr. Reddy's Laboratories
• Lupin
• Hetero Drugs Limited
• Glenmark Pharmaceuticals Limited
• ViiV Healthcare
What Are The Regional Insights Into The Acquired Immunodeficiency Syndrome AIDS Market?
North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (AIDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.